-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Talaris Therapeutics, Inc. (NASDAQ:TALS) Short Interest Up 22.5% in November
Talaris Therapeutics, Inc. (NASDAQ:TALS) Short Interest Up 22.5% in November
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 703,800 shares, a growth of 22.5% from the October 31st total of 574,700 shares. Based on an average daily trading volume, of 200,500 shares, the short-interest ratio is presently 3.5 days. Approximately 3.6% of the shares of the stock are sold short.
Hedge Funds Weigh In On Talaris Therapeutics
A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Talaris Therapeutics during the 3rd quarter worth approximately $27,000. Amalgamated Bank bought a new stake in Talaris Therapeutics during the 1st quarter worth approximately $31,000. Commonwealth Equity Services LLC bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Prospera Financial Services Inc bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Finally, Values First Advisors Inc. bought a new position in Talaris Therapeutics in the 2nd quarter valued at $53,000. 67.99% of the stock is owned by institutional investors and hedge funds.
Get Talaris Therapeutics alerts:Talaris Therapeutics Price Performance
Shares of NASDAQ TALS traded down $0.03 during trading hours on Thursday, hitting $1.43. 1,395 shares of the company's stock were exchanged, compared to its average volume of 141,180. Talaris Therapeutics has a 1-year low of $1.16 and a 1-year high of $16.63. The company's 50-day moving average price is $1.91 and its 200-day moving average price is $4.05.
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Research analysts anticipate that Talaris Therapeutics will post -1.86 EPS for the current year.Wall Street Analysts Forecast Growth
TALS has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th. Morgan Stanley lowered their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, September 9th. Finally, HC Wainwright started coverage on Talaris Therapeutics in a report on Thursday, October 20th. They set a "buy" rating and a $18.00 price target on the stock.
Talaris Therapeutics Company Profile
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 703,800 shares, a growth of 22.5% from the October 31st total of 574,700 shares. Based on an average daily trading volume, of 200,500 shares, the short-interest ratio is presently 3.5 days. Approximately 3.6% of the shares of the stock are sold short.
塔拉里斯治療公司(納斯達克代碼:TALS-GET Rating)在11月份看到空頭股數的大幅增長。截至11月15日,空頭股數共有70.38萬股,比10月31日的57.47萬股增長22.5%。以日均成交量200,500股計算,目前短息比為3.5天。大約3.6%的股票被賣空。
Hedge Funds Weigh In On Talaris Therapeutics
對衝基金入股Talaris Treeutics
A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Talaris Therapeutics during the 3rd quarter worth approximately $27,000. Amalgamated Bank bought a new stake in Talaris Therapeutics during the 1st quarter worth approximately $31,000. Commonwealth Equity Services LLC bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Prospera Financial Services Inc bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Finally, Values First Advisors Inc. bought a new position in Talaris Therapeutics in the 2nd quarter valued at $53,000. 67.99% of the stock is owned by institutional investors and hedge funds.
一些對衝基金最近調整了對該股的持有量。SG America Securities LLC在第三季度購買了Talaris Treeutics的新股份,價值約2.7萬美元。合併銀行在第一季度購買了Talaris治療公司的新股份,價值約3.1萬美元。英聯邦股權服務有限責任公司在第三季度購買了Talaris治療公司的一個新頭寸,價值34,000美元。普羅斯佩拉金融服務公司在第三季度購買了Talaris治療公司的一個新頭寸,價值34,000美元。最後,Values First Advisors Inc.在第二季度購買了Talaris治療公司的一個新頭寸,價值53,000美元。67.99%的股票由機構投資者和對衝基金持有。
Talaris Therapeutics Price Performance
Talaris治療公司的性價比
Shares of NASDAQ TALS traded down $0.03 during trading hours on Thursday, hitting $1.43. 1,395 shares of the company's stock were exchanged, compared to its average volume of 141,180. Talaris Therapeutics has a 1-year low of $1.16 and a 1-year high of $16.63. The company's 50-day moving average price is $1.91 and its 200-day moving average price is $4.05.
週四交易時段,新浪納斯達克的股價下跌0.03美元,至1.43美元。該公司股票成交量為1,395股,而其平均成交量為141,180股。Talaris Treeutics的一年低點為1.16美元,一年高位為16.63美元。該公司的50日移動均線價格為1.91美元,200日移動均線價格為4.05美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
TALS has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th. Morgan Stanley lowered their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, September 9th. Finally, HC Wainwright started coverage on Talaris Therapeutics in a report on Thursday, October 20th. They set a "buy" rating and a $18.00 price target on the stock.
TALS一直是最近多份分析師報告的主題。Evercore ISI在8月15日星期一的一份研究報告中將他們對Talaris治療公司的目標價上調至20.00美元。摩根士丹利在9月9日(星期五)的一份報告中將他們對Talaris Treeutics的目標價從8.00美元下調至6.00美元,並對該股設定了“同等權重”評級。最後,HC Wainwright在10月20日星期四的一份報告中開始報道Talaris治療公司。他們為該股設定了“買入”評級和18.00美元的目標價。
Talaris Therapeutics Company Profile
Talaris治療公司簡介
(Get Rating)
(獲取評級)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Talaris治療公司在美國作為一家臨牀晚期細胞治療公司運營。該公司致力於開發異基因造血幹細胞移植的方法,以改變實體器官移植和嚴重的自身免疫性疾病以及嚴重的非惡性血液、免疫和代謝疾病的護理標準。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- 免費獲取StockNews.com關於Talaris治療(TALS)的研究報告
- 賣空者對馬倫汽車股票的看法仍然正確嗎?
- La-Z-Boy傾斜到更舒適的水平
- 復甦集會是為SoFi而來的嗎?
- 蘋果會在年底前大漲嗎?
- 放寬Covid規則會降低中國電動汽車製造商蔚來的風險嗎?
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Talaris治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Talaris治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧